Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of PUFS are confirming the original effect size in real-world data.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0842
Recent follow-up analyses of ESCAPE are confirming the original effect size in real-world data.
0.0844
Recent follow-up analyses of SWIFT PRIME are confirming the original effect size in real-world data.
0.0933
Recent follow-up analyses of MEMBRANE are confirming the original effect size in real-world data.
0.0946
Recent follow-up analyses of DAWN are confirming the original effect size in real-world data.
0.0965
Recent follow-up analyses of EARLYSTIM are confirming the original effect size in real-world data.
0.1005
Recent follow-up analyses of ORBITA are confirming the original effect size in real-world data.